Background: Snake envenomation is a serious public health threat in the rural areas of Asian and African countries. To date, the only proven treatment for snake envenomation is antivenom therapy. Cross-neutralization of heterologous venoms by antivenom raised against venoms of closely related species has been reported. The present study examined the cross neutralizing potential of a newly developed polyvalent antivenom, termed Neuro Polyvalent Snake Antivenom (NPAV). NPAV was produced by immunization against 4 Thai elapid venoms.
Principal Findings: In vitro neutralization study using mice showed that NPAV was able to neutralize effectively the lethality of venoms of most common Asiatic cobras (Naja spp.), Ophiophagus hannah and kraits (Bungarus spp.) from Southeast Asia, but only moderately to weakly effective against venoms of Naja from India subcontinent and Africa. Studies with several venoms showed that the in vivo neutralization potency of the NPAV was comparable to the in vitro neutralization potency. NPAV could also fully protect against N. sputatrix venom-induced cardio-respiratory depressant and neuromuscular blocking effects in anesthetized rats, demonstrating that the NPAV could neutralize most of the major lethal toxins in the Naja venom.
Conclusions/significance: The newly developed polyvalent antivenom NPAV may find potential application in the treatment of elapid bites in Southeast Asia, especially Malaysia, a neighboring nation of Thailand. Nevertheless, the applicability of NPAV in the treatment of cobra and krait envenomations in Southeast Asian victims needs to be confirmed by clinical trials. The cross-neutralization results may contribute to the design of broad-spectrum polyvalent antivenom.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367981 | PMC |
http://dx.doi.org/10.1371/journal.pntd.0001672 | DOI Listing |
Toxicon
January 2025
Emergency Department, Setthatirath Hospital,Vientiane,Lao PDR.
Snakebite envenoming in pregnant women is rare, accounting for approximately 0.5-1.8% of all snakebite cases.
View Article and Find Full Text PDFTrans R Soc Trop Med Hyg
January 2025
Pharm-Biotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Faculty of Medicine, Mbarara University of Science and Technology, Mbarara 40006, Uganda.
Snake venom, a complex mixture of proteins, has attracted human attention for centuries due to its associated mortality, morbidity and other therapeutic properties. In sub-Saharan Africa (SSA), where snakebites pose a significant health risk, understanding the genetic variability of snake venoms is crucial for developing effective antivenoms. The wide geographic distribution of venomous snake species in SSA countries demonstrates the need to develop specific and broad antivenoms.
View Article and Find Full Text PDFTrop Med Infect Dis
December 2024
Institut Pasteur Medical Center, Paris Cité University, F-75015 Paris, France.
Snakes responsible for bites are rarely identified, resulting in a loss of information about snakebites from venomous species whose venom effects are poorly understood. A prospective clinical study including patients bitten by a snake was conducted in Cameroon between 2019 and 2021 to evaluate the efficacy and tolerability of a marketed polyvalent antivenom. Clinical presentation during the first 3 days of hospitalization was recorded following a standardized protocol.
View Article and Find Full Text PDFToxins (Basel)
December 2024
Poison Control Center, The University of Arizona College of Pharmacy, Tucson, AZ 85724, USA.
The onset, progression, and severity of pain following rattlesnake envenomation are highly variable between patients. Pain can be severe and persistent, seemingly refractory to opioid analgesics. The ability of antivenom to directly relieve pain has not been well studied.
View Article and Find Full Text PDFCureus
November 2024
Community Medicine, Dhanalakshmi Srinivasan Medical College and Hospital, Perambalur, IND.
Background Snakebite envenomation remains a significant public health challenge in tropical countries, particularly affecting the pediatric population. Children are especially vulnerable because of their smaller body mass, outdoor activities, and delayed presentation to healthcare facilities. This study aimed to analyze the clinical profile, demographic patterns, and envenomation characteristics of snakebites in children aged 1-16 years presenting to a tertiary care center.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!